Top

Pediatric Nephrology

Published in:

Open Access 01-08-2003 | Original Article

The management of anemia in pediatric peritoneal dialysis patients

Guidelines by an ad hoc European committee

Authors: Cornelis H. Schröder, The European Pediatric Peritoneal Dialysis Working Group

Published in: Pediatric Nephrology | Issue 8/2003

Abstract

Anemia is common in chronic renal failure. Guidelines for the diagnosis and treatment of anemia in adult patients are available. With respect to the diagnosis and treatment in children on peritoneal dialysis, the European Pediatric Peritoneal Dialysis Working Group (EPPWG) has produced guidelines. After a thorough diagnostic work-up, treatment should aim for a target hemoglobin concentration of at least 11 g/l. This can be accomplished by the administration of erythropoietin and iron preparations. Although there is sufficient evidence to advocate the intraperitoneal administration of erythropoietin, most pediatric nephrologists still apply erythropoietin by the subcutaneous route. Iron should preferably be prescribed as an oral preparation. Sufficient attention has to be paid to the nutritional intake in these children. There is no place for carnitine supplementation in the treatment of anemia in pediatric peritoneal dialysis patients.

National Kidney Foundation—Dialysis Outcomes Quality Initiative (NKF-DOQI) (1997) Clinical practice guidelines for the treatment of anemia. Am J Kidney Dis 30 (Suppl 3):192–240

National Kidney Foundation (2001) K/DOQI Clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis 37 (Suppl 1):182–238

European best practice guidelines for the management of anaemia in patients with chronic renal failure (1999) Nephrol Dial Transplant 14 (Suppl 5):1–50

Watson AR, Gartland C, on behalf of the European Pediatric Peritoneal Dialysis Working Group (2001) Elective chronic peritoneal dialysis in pediatric patients: guidelines by an ad hoc European committee. Perit Dial Int 21:240–244PubMed

Behrman RE, Kliegman R, Arvin AM (eds) (1996) Nelson textbook of pediatrics, 15th edn. WB Saunders, Philadelphia

MacDougall IC, Cavill I, Hulme B, Bain B, McGregor E, McCay P, Sanders E, Coles GA, Williams JD (1992) Detection of functional iron deficiency during erythropoietin treatment: a new approach. BMJ 304:471–472PubMed

Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG, Kleinman JG, Vaamonde CA (2001) Diagnostic value of iron indices in hemodialysis patients receiving epoetin. Kidney Int 60:300–308CrossRefPubMed

Stevens L, Stigant C, Levin A (2002) Should hemoglobin be normalized in patients with chronic kidney disease? Semin Dial 15:8–13CrossRefPubMed

Brandt JR, Avner ED, Hickman RO, Watkins SL (1999) Safety and efficacy of erythropoietin in children with chronic renal failure. Pediatr Nephrol 13:143–147PubMed

10.

Van Damme-Lombaerts R, Herman J (1999) Erythropoietin treatment in children with renal failure. Pediatr Nephrol 13:148–152CrossRefPubMed

11.

Weiss LG, Clyne N, Divino Fihlho J, Frisenette-Fich C, Kurkus J, Svensson B (2000) The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin β: results from a randomized controlled multicentre trial. Nephrol Dial Transplant 15:2014–2019CrossRefPubMed

12.

Locatelli F, Baldamus CA, Villa G, Ganea A, Martin de Francisco AL (2002) Once-weekly compared with three-times-weekly subcutaneous epoetin β: results from a randomized, multicenter, therapeutic-equivalence study. Am J Kidney Dis 40:119–125CrossRefPubMed

13.

Macdougall IC (2002) Once-weekly erythropoietic therapy: is there a difference between the available preparations? Nephrol Dial Transplant 17:2047–2051CrossRefPubMed

14.

Scigalla P, Bonzel KE, Bulla M, Burghard R, Dippel J, Geisert J, Leumann E, Von Lilien T, Müller-Wiefel DE, Offner GE (1989) Specific problems of renal anemia in childhood. Contrib Nephrol 76:227–240PubMed

15.

Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian J-J, Martin-Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I, Varet B, Mayeux P (2002) Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346:469–475PubMed

16.

Weber G, Gross J, Kromminga A, Loew H-H, Eckardt K-U (2002) Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenged with different epoetins. J Am Soc Nephrol 13:2381–2383PubMed

17.

Nicoletta P, Bernardini J, Dacko C, Terry C, Fried L (2000) Compliance with subcutaneous erythropoietin in peritoneal dialysis patients. Adv Perit Dial 16:90–92PubMed

18.

Wazny LD, Stojimirovic BB, Heidenheim P, Blake PG (2002) Factors influencing erythopoietin compliance in peritoneal dialysis patients. Am J Kidney Dis 40:623–628CrossRefPubMed

19.

Smith SL, Hindmarsh PC, Brook CGD (1993) Compliance with growth hormone treatment—are they getting it? Arch Dis Child 68:91–93PubMed

20.

Rees L (1997) Compliance with growth hormone therapy in chronic renal failure and post transplant. Pediatr Nephrol 11:752–754CrossRefPubMed

21.

Postlethwaite RJ, Eminson DM, Reynolds JM, Wood AJ, Hollis S (1998) Growth in renal failure: a longitudinal study of emotional and behavioural changes during trials of growth hormone treatment. Arch Dis Child 78:222–229PubMed

22.

Besarab A, Reyes CM, Hornberger J (2002) Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. Am J Kidney Dis 40:439–446CrossRefPubMed

23.

Boelaert JR, Schurgers ML, Matthijs EG, Belpaire FM, Daneels RF, De Cre MJ, Bogaert MG (1989) Comparative pharmacokinetics of recombinant erythropoietin administered by the intravenous, and intraperitoneal routes in continuous ambulatory peritoneal dialysis (CAPD) patients. Perit Dial Int 9:95–98PubMed

24.

MacDougall IC, Roberts DE, Neubert P, Dharmasena AD, Coles GA, Williams JD (1989) Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Lancet I:425–427

25.

Reddingius RE, Schröder CH, Koster AM, Monnens LAH (1994) Pharmacokinetics of recombinant human erythropoietin in children treated with continuous ambulatory peritoneal dialysis. Eur J Pediatr 153:850–854CrossRefPubMed

26.

Reddingius RE, Schröder CH, Monnens LAH (1992) Intraperitoneal administration of erythropoietin in children on continuous ambulatory peritoneal dialysis. Eur J Pediatr 151:540–542PubMed

27.

Reddingius RE, De Boer AW, Schröder CH, Willems JL, Monnens LAH (1997) Increase of the bioavailability of intraperitoneal erythropoietin in children on peritoneal dialysis by administration in small dialysis bags. Perit Dial Int 17:467–470PubMed

28.

Rusthoven E, Van de Kar NCAJ, Monnens LAH, Schröder CH (2001) Long term effectiveness of intraperitoneal erythropoietin in children on NIPD by administration in small bags. Perit Dial Int 21:196–197PubMed

29.

Offner G, Hoyer PF, Latta K, Winkler L, Brodehl J, Scigalla P (1990) One year's experience with recombinant erythropoietin in children undergoing continuous ambulatory peritoneal dialysis. Pediatr Nephrol 4:498–500PubMed

30.

MacDougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J, Egrie J (1999) Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 10:2392–2395PubMed

31.

Egrie JC, Browne JK (2001) Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 16 (Suppl 3):3–13

32.

MacDougall IC (2001) An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 16 (Suppl 3):14–21CrossRef

33.

Nissenson AR (2001) Novel erythropoiesis stimulating protein for managing the anemia of chronic kidney disease. Am J Kidney Dis 38:1390–1397PubMed

34.

MacDougall IC (2002) Darbepoetin alfa: a new therapeutic agent for renal anemia. Kidney Int 61 (Suppl 80):55–61CrossRef

35.

Lerner GR, Kale AS, Warady BA, Jabs K, Bunchman TE, Heatherington A, Olson K, Messer-Mann L, Maroni BJ (2002) Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease. Pediatr Nephrol 17:933–937CrossRefPubMed

36.

Johnson DL, Jolliffe LK (2000) Erythropoietin mimetic peptides and the future. Nephrol Dial Transplant 15:1274–1277CrossRefPubMed

37.

MacDougall IC (2001) Hyporesponsiveness to anemia therapy—what are we doing wrong? Perit Dial Int 21 (Suppl 3):225–230PubMed

38.

Seeherunvong W, Rubio L, Abitbol CL, Montané B, Strauss J, Diaz R, Zilleruelo G (2001) Identification of poor responders to erythopoietin among children undergoing hemodialysis. J Pediatr 138:710–714CrossRefPubMed

39.

Coleman JE, Edefonti A, Watson AR, and the European Paediatric Peritoneal Dialysis Working Group (2001) Guidelines by an ad hoc European committee on the assessment of growth and nutrition status in children on chronic peritoneal dialysis. Perit Dial Int 21: online publication

40.

Morton AR (2000) How should iron be given to peritoneal dialysis patients? Perit Dial Int 20:598–600PubMed

41.

Fishbane S, Wagner J (2001) Sodium ferric gluconate complex in the treatment of iron deficiency for patients on dialysis. Am J Kidney Dis 37:879–883PubMed

42.

Tenbrock K, Müller-Berghaus J, Michalk D, Querfeld U (1999) Intravenous iron treatment of renal anemia in children on hemodialysis. Pediatr Nephrol 13:580–582CrossRefPubMed

43.

Michael B, Coyne DW, Fishbane S, Folkert V, Lynn R, Nissenson AR, Agarwal R, Eschbach JW, Fadem SZ, Trout JR, Strobos J, Warnock DG (2002) Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran. Kidney Int 61:1830–1839CrossRefPubMed

44.

Yee J, Besarab A (2002) Iron sucrose: the oldest iron therapy becomes new. Am J Kidney Dis 40:1111–1121CrossRefPubMed

45.

Pecoits-Filho RFS, Twardowski ZJ, Kim Y-L, Khanna R, Moore H, Nolph KD (1998) The absence of toxicity in intraperitoneal iron dextran administration: a functional and histological analysis. Perit Dial Int 18:64–70PubMed

46.

Mars RL, Moles K, Pope K, Hargrove P (1999) Use of bolus intraperitoneal iron dextran in continuous ambulatory peritoneal dialysis or continuous cyclic peritoneal dialysis patients receiving recombinant human erythropoietin. Adv Perit Dial 15:60–64PubMed

47.

Reddy DK, Moore HL, Lee JH, Saran R, Nolph KD, Khanna R, Twardowski ZJ (2001) Chronic peritoneal dialysis in iron-deficient rats with solutions containing iron dextran. Kidney Int 59:764–773CrossRefPubMed

48.

Kavadias D, Fourtounas C, Tsouchnikas J, Barboutis K (1996)l-carnitine and erythropoietin requirements in hemodialysis patients. Am J Kidney Dis 28:156

49.

Boran M, Dalva I, Gouenç F, Çetin S (1996) Response to recombinant human erythropoietin (r-Hu EPO) and l-carnitine combination in patients with anemia of end-stage renal disease. Nephron 73:314–315PubMed

50.

Labonia WD (1995)l-carnitine effects on anemia in hemodialyzed patients treated with erythropoietin. Am J Kidney Dis 26:757–764PubMed

51.

Bérard E, Iordache A (1992) Effect of low doses of l-carnitine on the response to recombinant human erythropoietin in hemodialyzed children: about two cases. Nephron 62:368–369PubMed

52.

Lilien MR, Duran M, Quak JME, Frankhuisen JJ, Schröder CH (2000) Oral l-carnitine does not decrease erythropoietin requirement in pediatric dialysis. Pediatr Nephrol 15:17–20CrossRefPubMed

Title: The management of anemia in pediatric peritoneal dialysis patients
Guidelines by an ad hoc European committee
Authors: Cornelis H. Schröder
The European Pediatric Peritoneal Dialysis Working Group
Publication date: 01-08-2003
Publisher: Springer-Verlag
Published in: Pediatric Nephrology / Issue 8/2003
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-003-1126-0

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The management of anemia in pediatric peritoneal dialysis patients

Guidelines by an ad hoc European committee

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2003

Sodium and potassium clearances by the maturing kidney: clinical-molecular correlates

Hypercalcemia and distal renal tubular acidosis: an association not only in the newborn

Long-term linear growth of children with severe steroid-responsive nephrotic syndrome

Prevention of cardiac arrhythmias in pediatric patients with normotensive-hypokalemic tubulopathy

Genetic and metabolic determinants of increased plasma plasminogen activator inhibitor-1 activity in children with renal transplants

Reply to the letter from Kaneko et al.